Deucravacitinib by Bristol-Myers Squibb can help with psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and systemic lupus erythematosus.
Teclistamab by Johnson & Johnson is a new hope for refractory or relapsing multiple myeloma.
Roflumilast will cure plaque psoriasis in half of patients.
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Siponimod released by Novartis is an improved version of Gilenya.